


Phase I Clinical Study of Seneca Valley Virus (SVV-001), a Replication-Competent Picornavirus, in Advanced Solid Tumors with Neuroendocrine Features

Charles M. Rudin¹, John T. Poirier¹, Neil N. Senzer², Joseph Stephenson Jr.³, David Loesch⁴, Kevin D. Burroughs⁵, P. Seshidhar Reddy⁵, Christine L. Hann¹, Paul L. Hallenbeck⁵

¹Johns Hopkins University, Baltimore, MD, ²Mary Crowley Cancer Research Center, Dallas, TX, ³Cancer Center of the Carolinas, Greenville, SC, ⁴Indianapolis, IN, ⁵Neotropix, Inc., Malvern, PA



Supplemental Figure. Serial CT scans demonstrating tumor response to SVV-001. CT scan images from a patient with a poorly differentiated neuroendocrine tumor obtained prior to treatment and 6 weeks after treatment with SVV-001 (10^{10} vp/kg) are shown. This patient also had extensive abdominal disease, which remained stable but did not evidently decrease in size following SVV-001 administration.